DNL593
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for DNL593, covering 2026-01-15 to 2026-01-15. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) [Phase 1, Phase 2]